Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed May 17, 2023
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-05-15+40,000→ 40,000 totalExercise: $2.75From: 2024-05-15Exp: 2033-05-15→ Common Stock (40,000 underlying)
Footnotes (1)
- [F1]The stock option will vest in full on May 15, 2024, subject to the Reporting Person's continued service on such vesting date.